Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced that it has completed its trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A final safety review committee…
Sarama Resources Ltd. (“Sarama” or the “Company”) (ASX:SRR, TSX- V:SWA) is pleased to advise that it has reached binding…
Rare earth metal production was on the rise again in 2023, jumping to 350,000 metric tons (MT) worldwide —…
Bitcoin is prone to price volatility, with wide swings to the upside and downside. There has been renewed interest…
NVIDIA’s (NASDAQ:NVDA) results have once again exceeded analysts’ expectations. Despite bearish sentiment leading up to the release of its…
Here’s a quick recap of the crypto landscape for Wednesday (February 26) as of 9:00 p.m. UTC. Bitcoin and…
Strata Minerals Limited (ASX: SMX, “Strata” or “the Company”) is pleased to announce commencement of a maiden drill program…
Red Metal Resources Ltd. (CSE: RMES) (OTC Pink: RMESF) (FSE: I660) (‘Red Metal’ or the ‘Company’) is pleased to…
Cleo Diagnostics (COV:AU) has announced Appendix 4D and Half Yearly Accounts Download the PDF here. This post appeared first…